Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX24.222,14-0,02 %

Gold3.358,29+0,43 %

Öl (Brent)69,18-2,00 %

Dow Jones44.456,79+0,25 %

US Tech 10022.862,35+0,36 %

EUR/USD1,16779+0,11 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

ANI Pharmaceuticals Aktie

Aktie

ISIN: US00182C1036 WKN: A1W15D SYM: ANIP Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

65,19

USD

+0,35 %

+0,23 USD

Letzter Kurs 02:00:00 Nasdaq

ANI Pharmaceuticals Aktie kaufen

Geldkurs

14.07.25

65,19

USD

200 STK

Briefkurs

14.07.25

65,29

USD

100 STK

BEI SMARTBROKER+ HANDELN

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Baader Tragding

Neueste Nachrichten

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th 02.07.25 · globenewswire · ANI Pharmaceuticals
ANI Pharmaceuticals Announces Presentation of New Preclinical Data 12.06.25 · globenewswire · ANI Pharmaceuticals
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference 27.05.25 · globenewswire · ANI Pharmaceuticals
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin Gel for the Treatment of Acute Gout Flares 22.05.25 · globenewswire · ANI Pharmaceuticals
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ 13.05.25 · globenewswire · ANI Pharmaceuticals
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance 09.05.25 · globenewswire · ANI Pharmaceuticals
ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model 05.05.25 · globenewswire · ANI Pharmaceuticals
Insider-Trades: Directors' Dealings – Die wichtigsten Transaktionen - KW 16/25 20.04.25 · Directors Dealings · 1-800-Flowers.com (A)
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8: 00 a.m. ET 09.04.25 · globenewswire · ANI Pharmaceuticals
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference 31.03.25 · globenewswire · ANI Pharmaceuticals
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets 19.03.25 · globenewswire · ANI Pharmaceuticals
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN and YUTIQ 18.03.25 · globenewswire · ANI Pharmaceuticals

1
2
3
…
4

Meistgelesen

30 Tage
12 Monate

ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th 116 Leser

ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering 724 Leser
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference 504 Leser
Insider-Trades: Directors' Dealings – Die wichtigsten Transaktionen - KW 16/25 496 Leser
ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering 444 Leser
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences 436 Leser
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel Prefilled Syringe 420 Leser
ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full ... 380 Leser
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences 376 Leser
ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral ... 336 Leser
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners ... 316 Leser